Solange Peters

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


509 publications

En préparation
 
Distinct immune signatures are a potent tool in the clinical management of cytokine-related syndrome during immune checkpoint therapy
Daoudlarian Douglas, Segot Amandine, Latifyan Sofiya, Bartolini Robin, Joo Victor, Mederos Nuria, Bouchaab Hasna, Demicheli Rita, Abdelhamid Karim, Ferahta Nabila et al..
[DOI][serval:BIB_818D0F24F67B]
 
Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study
Petit Pierre-Florent, Daoudlarian Douglas, Latifyan Sofiya, Bouchaab Hasna, Mederos Nuria, Doms Jacqueline, Abdelhamid Karim, Ferahta Nabila, Mencarelli Lucrezia, Joo Victor et al..
[DOI][serval:BIB_34BED0C92D50]
Sous presse
 
Proceedings of the 1st biannual bridging the gaps in lung cancer conference.
Florez N., Patel S.P., Wakelee H., Bazhenova L., Massarelli E., Salgia R., Stiles B., Peters S., Malhotra J., Gadgeel S.M. et al. The oncologist. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A6408ED80877]
 
Identifying the drivers of overall rating of cancer care: Insights from the second wave of the Swiss Cancer Patient Experiences study.
Jolidon V., Eicher M., Peytremann-Bridevaux I., Aebi S., Anchisi S., Bettini A., Chalandon Y., Dietrich P.Y., Duchosal M.A., Dürr D. et al. Cancer. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0A518D224843]
 
Calls to action on lung cancer management and research.
Meyer M.L., Hirsch F.R., Bunn P.A., Ujhazy P., Fredrickson D., Berg C.D., Carbone D.P., Halmos B., Singh H., Borghaei H. et al. The oncologist. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_554AFB6D6C3A]
 
Lung Cancer Research and Treatment: Global Perspectives and Strategic Calls to Action.
Meyer M.L., Peters S., Mok T.S., Lam S., Yang P.C., Aggarwal C., Brahmer J., Dziadziuszko R., Felip E., Ferris A. et al. Annals of oncology. Peer-reviewed.
[DOI][Pmid][serval:BIB_F9174A4758FA]
 
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes from the Phase 3 POSEIDON Trial.
Peters S., Cho B.C., Luft A.V., Alatorre-Alexander J., Geater S.L., Laktionov K., Trukhin D., Kim S.W., Ursol G.M., Hussein M. et al. Journal of thoracic oncology. Peer-reviewed.
[DOI][Pmid][serval:BIB_9D803F1B2F65]
 
Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic Non-Small Cell Lung Cancer and Tumor PD-L1 <1%: a Pooled Analysis.
Peters S., Paz-Ares L.G., Reck M., Carbone D.P., Brahmer J.R., Borghaei H., Lu S., O'Byrne K.J., John T., Ciuleanu T.E. et al. Journal of thoracic oncology. Peer-reviewed.
[DOI][Pmid][serval:BIB_89D370D6F09D]
 
Landscape of subsequent therapies in perioperative immunotherapy trials across multiple cancer types.
Semaan K., Nawfal R., Nally E., Janjigian Y.Y., Robert C., Peters S., Powles T., Choueiri T.K. The Lancet. Oncology. Peer-reviewed.
[DOI][Pmid][serval:BIB_7F720847BE91]
2024
 
ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial.
Soo R.A., Dafni U., Han J.Y., Cho B.C., Nadal E., Yeo C.M., Carcereny E., de Castro J., Sala M.A., Coate L. et al., 2024/11/15. Clinical cancer research, 30 (22) pp. 5180-5191. Peer-reviewed.
[DOI][Pmid][serval:BIB_CD5E14800EE8]
 
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Skoulidis F., Araujo H.A., Do M.T., Qian Y., Sun X., Cobo A.G., Le J.T., Montesion M., Palmer R., Jahchan N. et al., 2024/11. Nature, 635 (8038) pp. 462-471. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CF6BDAC4D159]
Multicenter Study on Tumor Budding in Lung Squamous Cell Carcinoma: Comparison Between Biopsy and Resection With Interobserver Variability Assessment.
Maillard M., Neppl C., Zens P., Anex J., Peters S., Krueger T., Berezowska S., 2024/10. Modern pathology, 37 (10) p. 100571. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B6BDDE9C1217]
 
Tumour mutational burden: clinical utility, challenges and emerging improvements.
Budczies J., Kazdal D., Menzel M., Beck S., Kluck K., Altbürger C., Schwab C., Allgäuer M., Ahadova A., Kloor M. et al., 2024/10. Nature reviews. Clinical oncology, 21 (10) pp. 725-742. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9751CA3C1CED]
 
Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study.
Petit P.F., Daoudlarian D., Latifyan S., Bouchaab H., Mederos N., Doms J., Abdelhamid K., Ferahta N., Mencarelli L., Joo V. et al., 2024/09/04. Annals of oncology. Peer-reviewed.
[DOI][Pmid][serval:BIB_0BA6393BFB37]
 
Reply to the Letter to the Editor regarding 'Overcoming Barriers in Biomarker Testing' J. García-Foncillas et al.
Bayle A., Chaltiel D., Latino N., Rouleau E., Peters S., Galotti M., Bricalli G., Besse B., Giuliani R., Bonastre J., 2024/09. Annals of oncology, 35 (9) pp. 829-830. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AA629501C5B1]
 
New promises and challenges in the treatment of advanced non-small-cell lung cancer.
Meyer M.L., Fitzgerald B.G., Paz-Ares L., Cappuzzo F., Jänne P.A., Peters S., Hirsch F.R., 2024/08/24. Lancet, 404 (10454) pp. 803-822. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8FD91D24F28E]
 
KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma.
Budczies J., Romanovsky E., Kirchner M., Neumann O., Blasi M., Schnorbach J., Shah R., Bozorgmehr F., Savai R., Stiewe T. et al., 2024/08. British journal of cancer, 131 (3) pp. 524-533. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0BE58CAF6E6A]
 
ROS1 fusions in resected stage I-III adenocarcinoma: Results from the European Thoracic Oncology Platform Lungscape project.
Speel E.M., Dafni U., Thunnissen E., Hendrik Rüschoff J., O'Brien C., Kowalski J., Kerr K.M., Bubendorf L., Sansano I., Joseph L. et al., 2024/08. Lung cancer, 194 p. 107860. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_40811E238763]
Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non-small cell lung cancer, and renal cell carcinoma.
Luke J.J., Long G.V., Robert C., Carlino M.S., Choueiri T.K., Haas N.B., O'Brien M., Paz-Ares L., Peters S., Powles T. et al., 2024/08. European journal of cancer, 207 p. 114146. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_31E8589807FD]
 
Testing new anticancer drugs before curative locoregional therapies: MDICT 2024 recommendations
Methodology for the Development of Innovative Cancer Therapies Taskforce, Stathis A., Le Tourneau C., Tan DSW, Melero I., Garralda E., Peters S., Postel-Vinay S., Yap TA, Martins-Branco D. et al., 2024/08. ESMO Open, 9 (8) p. 103649.
[DOI][WoS][Pmid][serval:BIB_8C8AF2A6E0A9]
 
Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation.
Peters S., Loi S., André F., Chandarlapaty S., Felip E., Finn S.P., Jänne P.A., Kerr K.M., Munzone E., Passaro A. et al., 2024/07. Annals of oncology, 35 (7) pp. 607-629. Peer-reviewed.
[DOI][Pmid][serval:BIB_A510AA983B34]
 
Brief Report: Impact of Anti-Cancer Treatments on Outcomes of COVID-19 in Patients With Thoracic Cancers: A CCC19 Registry Analysis.
Kulkarni A.A., Hennessy C., Wilson G., Ramesh V., Hwang C., Awosika J., Bakouny Z., Khan H., Vilar-Compte D., McKay R. et al., 2024/07. Clinical lung cancer, 25 (5) pp. e229-e237.e7. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_90D4C066D942]
Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial.
Peters S., Gadgeel S.M., Mok T., Nadal E., Kilickap S., Swalduz A., Cadranel J., Sugawara S., Chiu C.H., Yu C.J. et al., 2024/07. Nature medicine, 30 (7) pp. 1923-1932. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4756E179C811]
 
Beyond Chemoimmunotherapy in Advanced Non-Small Cell Lung Cancer: New Frontiers, New Challenges.
Mountzios G., Naidoo J., Wang C., Creelan B.C., Trotier D.C., Campbell T.C., Peters S., 2024/06. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 44 (3) pp. e432526. Peer-reviewed.
[DOI][Pmid][serval:BIB_67724FD69311]
 
Deep mapping of the cytokine release syndrome inflammatory continuum: Comprehensive grade-specific profiling and differentiation from sepsis in patients receiving immune checkpoint therapy.
Obeid Michel, Daoudlarian Douglas, Segot Amandine, Latifyan Sofiya, Bouchaab Hasna, Mederos Nuria, Abdelhamid Karim, Ferahta Nabila, Stravodimou Athina, Shabafrouz Keyvan et al., 2024/06/01. Journal of Clinical Oncology, 42 (16_suppl) pp. 12129-12129.
[DOI][serval:BIB_928272EB14D0]
 
High-dimensional longitudinal immune profiling uncovers a dual role of the CXCL9/CXCR3, CXCL13/CXCR5, and CCL11/CCL3 axis in the coupling of immune-related adverse events to immune checkpoint inhibitor response.
Obeid Michel, Joo Victor, Daoudlarian Douglas, Bartolini Robin, Bouchaab Hasna, Latifyan Sofiya, Mederos Nuria, Abdelhamid Karim, Mosimann Valérie, Ferahta Nabila et al., 2024/06/01. Journal of Clinical Oncology, 42 (16_suppl) pp. 2512-2512.
[DOI][serval:BIB_DDD63EA0571E]
NTRK gene fusion testing and management in lung cancer.
Repetto M., Chiara Garassino M., Loong H.H., Lopez-Rios F., Mok T., Peters S., Planchard D., Popat S., Rudzinski E.R., Drilon A. et al., 2024/06. Cancer treatment reviews, 127 p. 102733. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_323D0B921E32]
 
Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R.
Filippi A.R., Bar J., Chouaid C., Christoph D.C., Field J.K., Fietkau R., Garassino M.C., Garrido P., Haakensen V.D., Kao S. et al., 2024/06. ESMO open, 9 (6) p. 103464. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8BA41A1F1CC3]
 
L’immunothérapie en oncologie : entre espoirs, défis et équité.
Peters S., Addeo A., Herrera F.G., 2024/05/15. Revue medicale suisse, 20 (874) pp. 951-952. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_7C68C1FA4B60]
 
Prise en charge des métastases osseuses du cancer pulmonaire non à petites cellules [Management of bone metastasis in non-small cell lung cancer]
Apeiranthiti A., Vanniere F., Bayoumy K., Christofis M., Serena A., Mosimann V., Abdelhamid K., Papadopoulos S., Nguyen-Ngoc T., Bouchaab H. et al., 2024/05/15. Revue medicale suisse, 20 (874) pp. 973-977. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_3949B97C5845]
A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study.
Garon E.B., Cho B.C., Luft A., Alatorre-Alexander J., Geater S.L., Trukhin D., Kim S.W., Ursol G., Hussein M., Lim F.L. et al., 2024/05. Clinical lung cancer, 25 (3) pp. 266-273.e5. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7A92BC1E6EB4]
Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma.
Joo V., Abdelhamid K., Noto A., Latifyan S., Martina F., Daoudlarian D., De Micheli R., Pruijm M., Peters S., Hullin R. et al., 2024/04/30. Nature communications, 15 (1) p. 3664. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4D3A2A46F635]
Long-Term Results of Stereotactic Radiotherapy in Patients with at Least 10 Brain Metastases at Diagnosis.
Kinj R., Hottinger A.F., Böhlen T.T., Ozsahin M., Vallet V., Dunet V., Bouchaab H., Peters S., Tuleasca C., Bourhis J. et al., 2024/04/29. Cancers, 16 (9). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_51F2E37A9F70]
 
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors.
Peters S., Angevin E., Alonso-Gordoa T., Rohrberg K., Melero I., Mellado B., Perez-Gracia J.L., Tabernero J., Adessi C., Boetsch C. et al., 2024/04/15. Clinical cancer research, 30 (8) pp. 1630-1641. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CC842A12DADF]
 
Adjuvant Alectinib in ALK-Rearranged NSCLC - Here and Now.
Passaro A., Peters S., 2024/04/11. The New England journal of medicine, 390 (14) pp. 1325-1327. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A545924B1B46]
 
Current strategies of cell and gene therapy for solid tumors: results of the joint international ESMO and CTIWP-EBMT survey.
Comoli P., Pentheroudakis G., Ruggeri A., Koehl U., Lordick F., Mooyaart J.E., Hoogenboom J.D., Urbano-Ispizua A., Peters S., Kuball J. et al., 2024/04. Annals of oncology, 35 (4) pp. 404-406. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C8DF2F8D0C82]
 
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment.
Passaro A., Al Bakir M., Hamilton E.G., Diehn M., André F., Roy-Chowdhuri S., Mountzios G., Wistuba I.I., Swanton C., Peters S., 2024/03/28. Cell, 187 (7) pp. 1617-1635. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BA8F740FDA43]
 
Lung Cancer in Switzerland.
Werner R.S., Curioni-Fontecedro A., Mauti L.A., Addeo A., Peters S., Frauenfelder T., Puhan M.A., Haberecker M., Bubendorf L., Finazzi T. et al., 2024/03. Journal of thoracic oncology, 19 (3) pp. 385-394. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_58F75E8C0494]
 
First-Line Dual Immunotherapy, a Treatment Option in First-Line Metastatic Non-Small-Cell Lung Cancer: Are We Ready to Use It?
Uprety D., Remon J., Peters S., 2024/02/01. Journal of clinical oncology, 42 (4) pp. 378-382. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FCBB794FB641]
Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases.
Peters S., Trigo J., Besse B., Moreno V., Navarro A., Eugenia Olmedo M., Paz-Ares L., Grohé C., Antonio Lopez-Vilariño J., Fernández C. et al., 2024/02. Lung cancer, 188 p. 107448. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_251547356E4A]
 
Oncologie: ce qui a changé en 2023 [Oncology: what's new in 2023]
Jankovic J., Abdelhamid K., Berthold D., Desbaillets N., Bouchaab H., Dei Tos G., Demicheli R., Diciolla A., Digklia A., Ferraro D.A. et al., 2024/01/17. Revue medicale suisse, 20 (856-7) pp. 80-87. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_126B4D3C8255]
 
A pharmacist-led interprofessional medication adherence program improved adherence to oral anticancer therapies: The OpTAT randomized controlled trial.
Bandiera C., Cardoso E., Locatelli I., Zaman K., Diciolla A., Digklia A., Stravodimou A., Cristina V., Aedo-Lopez V., Dolcan A. et al., 2024. PloS one, 19 (6) pp. e0304573. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_43D02C36CEB4]
 
Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT).
Gridelli C., Peters S., Mok T., Garassino M., Paz-Ares L., Attili I., de Marinis F., 2024/01. Lung cancer, 187 p. 107441. Peer-reviewed.
[DOI][Pmid][serval:BIB_9749AF3A1EE0]
 
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.
Borghaei H., de Marinis F., Dumoulin D., Reynolds C., Theelen WSME, Percent I., Gutierrez Calderon V., Johnson M.L., Madroszyk-Flandin A., Garon E.B. et al., 2024/01. Annals of oncology, 35 (1) pp. 66-76. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1ED7B5418D24]
 
The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies.
Shapira-Frommer R., Niu J., Perets R., Peters S., Shouse G., Lugowska I., Garassino M.C., Sands J., Keenan T., Zhao B. et al., 2024. Future oncology, 20 (27) pp. 1983-1991. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0B8C6BE1D41B]
2023
Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT).
Burns L., Hsu C.Y., Whisenant J.G., Marmarelis M.E., Presley C.J., Reckamp K.L., Khan H., Jo Fidler M., Bestvina C.M., Brahmer J. et al., 2023/12. Lung cancer, 186 p. 107423. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_399574E2CC5C]
Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON).
Garon E.B., Cho B.C., Luft A., Alatorre-Alexander J., Geater S.L., Kim S.W., Ursol G., Hussein M., Lim F.L., Yang C.T. et al., 2023/12. Lung cancer, 186 p. 107422. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_709D1EB4530B]
 
Dépistage du cancer pulmonaire : vers l’implémentation d’un projet pilote en Suisse [Lung cancer screening : towards the implementation of a pilot project in Switzerland]
Bongard C., Rey Cobo J., Messe R., Noirez L., Lovis A., Krueger T., Peters S., Pozzessere C., Selby K., von Garnier C., 2023/11/15. Revue medicale suisse, 19 (850) pp. 2165-2171. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_C20779B2000E]
Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial.
Lim S.M., Peters S., Ortega Granados A.L., Pinto GDJ, Fuentes C.S., Lo Russo G., Schenker M., Ahn J.S., Reck M., Szijgyarto Z. et al., 2023/11/11. Nature communications, 14 (1) p. 7301. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D6E420A37DBF]
Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC.
Kim H.R., Awad M.M., Navarro A., Gottfried M., Peters S., Csőszi T., Cheema P.K., Rodriguez-Abreu D., Wollner M., Yang J.C. et al., 2023/11. JTO clinical and research reports, 4 (11) p. 100572. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_7EBE3AF70615]
 
1452P Factors associated with real-world (rw) outcomes among pts with metastatic NSCLC (mNSCLC) receiving select immuno-oncology (IO) regimens: CORRELATE
Liu S.V., Salomonsen R.J-B., Diaz Perez I., Wang A., Cai L., Schmidt J., Sadow S., Peters S., 2023/10., ESMO Congress 2023, 20 - 24 October 2023 pp. S825-S826 dans Annals of Oncology.
[DOI][WoS][serval:BIB_549CA609CC08]
 
ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe.
Bayle A., Bonastre J., Chaltiel D., Latino N., Rouleau E., Peters S., Galotti M., Bricalli G., Besse B., Giuliani R., 2023/10. Annals of oncology, 34 (10) pp. 934-945. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BB80FB84CE17]
 
Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges.
Mountzios G., Remon J., Hendriks LEL, García-Campelo R., Rolfo C., Van Schil P., Forde P.M., Besse B., Subbiah V., Reck M. et al., 2023/10. Nature reviews. Clinical oncology, 20 (10) pp. 664-677. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0FB0D505E36B]
Leptomeningeal metastasis from solid tumours: EANO-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Le Rhun E., Weller M., van den Bent M., Brandsma D., Furtner J., Rudà R., Schadendorf D., Seoane J., Tonn J.C., Wesseling P. et al., 2023/10. ESMO open, 8 (5) p. 101624. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3F6C44F4DCB8]
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma.
Homicsko K., Zygoura P., Norkin M., Tissot S., Shakarishvili N., Popat S., Curioni-Fontecedro A., O'Brien M., Pope A., Shah R. et al., 2023/10. Journal for immunotherapy of cancer, 11 (10). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_03AE420D2700]
Response to letter entitled: letter comments on: Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation.
Gosney J.R., Peters S., 2023/10. ESMO open, 8 (5) p. 101828. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_E0A055E006B6]
 
Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19
Gulati Shuchi, Hsu Chih-Yuan, Shah Surbhi, Shah Pankil K., Zon Rebecca, Alsamarai Susan, Awosika Joy, El-Bakouny Ziad, Bashir Babar, Beeghly Alicia et al., 2023/10/01. JAMA Oncology, 9 (10) p. 1390.
[DOI][WoS][Pmid][serval:BIB_12CBCEF74E70]
 
European Epidemiology of Pleural Mesothelioma-Real-Life Data From a Joint Analysis of the Mesoscape Database of the European Thoracic Oncology Platform and the European Society of Thoracic Surgery Mesothelioma Database.
Opitz I., Bille A., Dafni U., Nackaerts K., Ampollini L., de Perrot M., Brcic L., Nadal E., Syrigos K., Gray S.G. et al., 2023/09. Journal of thoracic oncology, 18 (9) pp. 1233-1247. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_82EE065BEEA5]
 
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study.
Lee S.M., Schulz C., Prabhash K., Kowalski D., Szczesna A., Han B., Rittmeyer A., Talbot T., Vicente D., Califano R. et al., 2023/08/05. Lancet, 402 (10400) pp. 451-463. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4B87FA7A77E6]
 
Adjuvant Treatments for Surgically Resected Non-Small Cell Lung Cancer Harboring EGFR Mutations: A Review.
Passaro A., Mok TSK, Attili I., Wu Y.L., Tsuboi M., de Marinis F., Peters S., 2023/08/01. JAMA oncology, 9 (8) pp. 1124-1131. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_30B1F260B901]
Learning lessons from the COVID-19 pandemic for real-world evidence research in oncology-shared perspectives from international consortia.
Castelo-Branco L., Lee R., Brandão M., Cortellini A., Freitas A., Garassino M., Geukens T., Grivas P., Halabi S., Oliveira J. et al., 2023/08. ESMO open, 8 (4) p. 101596. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5A744A2C49A9]
Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation.
Gosney J.R., Paz-Ares L., Jänne P., Kerr K.M., Leighl N.B., Lozano M.D., Malapelle U., Mok T., Sheffield B.S., Tufman A. et al., 2023/08. ESMO open, 8 (4) p. 101587. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0803E2B8A7EF]
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1.
Reck M., Ciuleanu T.E., Lee J.S., Schenker M., Zurawski B., Kim S.W., Mahave M., Alexandru A., Peters S., Pluzanski A. et al., 2023/08. Journal of thoracic oncology, 18 (8) pp. 1055-1069. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9890E6F11421]
 
Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies.
Passaro A., Jänne P.A., Peters S., 2023/07/20. Journal of clinical oncology, 41 (21) pp. 3747-3761. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D5BA313EAC7F]
The Utility of ctDNA in Lung Cancer Clinical Research and Practice: A Systematic Review and Meta-Analysis of Clinical Studies.
Sun X., Abrahamson P., Ballew N., Kalilani L., Phiri K., Bell K.F., Slowley A., Zajac M., Hofstatter E., Stojadinovic A. et al., 2023/07. Cancer investigation, 41 (6) pp. 571-592. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F4BE601CAEA2]
 
Outcomes of Stage IIIa and Well-Selected Stage IIIb or Oligometastatic Stage IV Non-Small Cell Lung Cancers Managed by Multimodal Therapy Including Immunotherapy and Surgery
Forster C, Abdelnour-Berchtold E, Chriqui L E, Bouchaab H, Peters S, Gonzalez M, Krueger T, Perentes J Y, 2023/06/09. dans British Journal of Surgery.
[DOI][WoS][serval:BIB_B98147D74089]
COVID-19 in cancer patients: update from the joint analysis of the ESMO-CoCARE, BSMO, and PSMO international databases.
Martin P., Tsourti Z., Ribeiro J., Castelo-Branco L., de Azambuja E., Gennatas S., Rogado J., Sekacheva M., Šušnjar S., Viñal D. et al., 2023/06. ESMO open, 8 (3) p. 101566. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_94155F804FBD]
Cytokine storm complicated by cardiogenic shock induced by anti-HER2 therapies.
Godinho R., Noto A., Fenwick C., Stravodimou A., Hugelshofer S., Peters S., Hullin R., Obeid M., 2023/06. Journal for immunotherapy of cancer, 11 (6). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D3B4F544BDF7]
Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial.
Girard N., Ponce Aix S., Cedres S., Berghmans T., Burgers S., Toffart A.C., Popat S., Janssens A., Gervais R., Hochstenbag M. et al., 2023/06. ESMO open, 8 (3) p. 101576. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B5CFBB1D0A86]
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer.
Im S.A., Gennari A., Park Y.H., Kim J.H., Jiang Z.F., Gupta S., Fadjari T.H., Tamura K., Mastura M.Y., Abesamis-Tiambeng MLT et al., 2023/06. ESMO open, 8 (3) p. 101541. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_833FEAFDA3E9]
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer.
Yoshino T., Cervantes A., Bando H., Martinelli E., Oki E., Xu R.H., Mulansari N.A., Govind Babu K., Lee M.A., Tan C.K. et al., 2023/06. ESMO open, 8 (3) p. 101558. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_FC6A285A7C21]
 
Spatial profiling of the microenvironment reveals low intratumoral heterogeneity and STK11-associated immune evasion in therapy-naïve lung adenocarcinomas.
Goldschmid H., Kluck K., Ball M., Kirchner M., Allgäuer M., Winter H., Herth F., Heußel C.P., Pullamsetti S.S., Savai R. et al., 2023/06. Lung cancer, 180 p. 107212. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_94DA50B976B3]
Tobacco cessation and the role of ESMO and medical oncologists: addressing the specific needs of cancer patients in times of the COVID-19 pandemic.
Krech R., Peters S., Kroemer H., Fu D., Giuliani R., Sehouli J., Ilbawi A., Prasad V., Ullrich A., 2023/06. ESMO open, 8 (3) p. 101579. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_348B9946FD46]
Carrières en oncologie et leadership féminin : les progrès sont-ils au point mort ?
Peters S., Addeo A., Aapro M., 2023/05/17. Revue medicale suisse, 19 (827) pp. 929-930. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_DF4B416E037D]
Immunotherapy-based combinations in metastatic NSCLC.
Desai A., Peters S., 2023/05. Cancer treatment reviews, 116 p. 102545. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_74C72B664E9F]
 
Population pharmacokinetic modelling of tremelimumab in patients with advanced solid tumours and the impact of disease status on time-varying clearance.
Hwang M., Chia Y.L., Zheng Y., Chen C.C., He J., Song X., Zhou D., Goldberg S.B., Siu L.L., Planchard D. et al., 2023/05. British journal of clinical pharmacology, 89 (5) pp. 1601-1616. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_49EDEBE6BC65]
Adjuvant therapies in stages I-III epidermal growth factor receptor-mutated lung cancer: current and future perspectives.
Kris M.G., Mitsudomi T., Peters S., 2023/04/28. Translational lung cancer research, 12 (4) pp. 824-836. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_68C5CE6F566B]
Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey.
Linardou H., Adjei A.A., Bajpai J., Banerjee S., Berghoff A.S., Mathias C.C., Choo S.P., Dent R., Felip E., Furness AJS et al., 2023/04. ESMO open, 8 (2) p. 100781. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F95E2DE28E52]
 
Immunotherapy in the first-line treatment of elderly patients with advanced non-small-cell lung cancer: results of an International Experts Panel Meeting by the Italian Association of Thoracic Oncology (AIOT).
Gridelli C., Peters S., Velcheti V., Attili I., de Marinis F., 2023/04. ESMO open, 8 (2) p. 101192. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6ABA6C8DB138]
 
Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Hendriks L.E., Kerr K.M., Menis J., Mok T.S., Nestle U., Passaro A., Peters S., Planchard D., Smit E.F., Solomon B.J. et al., 2023/04. Annals of oncology, 34 (4) pp. 358-376. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0E714965871B]
 
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Hendriks L.E., Kerr K.M., Menis J., Mok T.S., Nestle U., Passaro A., Peters S., Planchard D., Smit E.F., Solomon B.J. et al., 2023/04. Annals of oncology, 34 (4) pp. 339-357. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2DAD09CAD00B]
 
The SERENITY study: online Mindfulness-Based Cancer Recovery (e-MBCR) program for women living with breast and gynecological cancer—protocol for a pilot effectiveness-implementation randomized trial
Gaignard Marie-Estelle, Stanic Jelena, Bodmer Alexandre, Zaman Khalil, Sarivalasis Apostolos, Labidi-Galy Intidhar, Jermann Francoise, Di Marco Mariagrazia, Ljuslin Michael, Ryser Stephan et al., 2023/04. Journal of Psychosocial Oncology Research &amp; Practice, 5 (2).
[DOI][serval:BIB_837DAB9F23E5]
 
A neutrophil response linked to tumor control in immunotherapy.
Gungabeesoon J., Gort-Freitas N.A., Kiss M., Bolli E., Messemaker M., Siwicki M., Hicham M., Bill R., Koch P., Cianciaruso C. et al., 2023/03/30. Cell, 186 (7) pp. 1448-1464.e20. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_75BDBCD58180]
 
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial.
de Langen A.J., Johnson M.L., Mazieres J., Dingemans A.C., Mountzios G., Pless M., Wolf J., Schuler M., Lena H., Skoulidis F. et al., 2023/03/04. Lancet, 401 (10378) pp. 733-746. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_610E00846F6E]
 
Assoziation von KRAS/STK11/KEAP1 Mutationen und Outcome in der POSEIDON Studie: Durvalumab+/− Tremelimumab+Chemotherapie beim metastasierten NSCLC (mNSCLC)
Reinmuth N, Peters S, Cho B, Luft A, Alatorre-Alexander J, Geater S, Kim S, Ursol G, Hussein M, Lim F et al., 2023/03. dans 63. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V..
[DOI][WoS][serval:BIB_BEC283C28682]
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.
Johnson M.L., Cho B.C., Luft A., Alatorre-Alexander J., Geater S.L., Laktionov K., Kim S.W., Ursol G., Hussein M., Lim F.L. et al., 2023/02/20. Journal of clinical oncology, 41 (6) pp. 1213-1227. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_50248B9218E8]
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer.
Koppikar S., Oaknin A., Babu K.G., Lorusso D., Gupta S., Wu L.Y., Rajabto W., Harano K., Hong S.H., Malik R.A. et al., 2023/02. ESMO open, 8 (1) p. 100774. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_236602D3C3F5]
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study.
Girard N., Bar J., Garrido P., Garassino M.C., McDonald F., Mornex F., Filippi A.R., Smit HJM, Peters S., Field J.K. et al., 2023/02. Journal of thoracic oncology, 18 (2) pp. 181-193. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D36FA0602240]
 
Oncologie : ce qui a changé en 2022 [Oncology: what's new in 2022]
Nguyen-Ngoc T., Abdelhamid K., Degrauwe N., Galland S., Serena A., Christofis M., Mederos N., Bouchaab H., Diciolla A., Dris N. et al., 2023/01/18. Revue medicale suisse, 19 (N° 809-10) pp. 52-57. Peer-reviewed.
[DOI][Pmid][serval:BIB_FAF585D3813B]
Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study.
Bandiera C., Locatelli I., Courlet P., Cardoso E., Zaman K., Stravodimou A., Dolcan A., Sarivalasis A., Zurcher J.P., Aedo-Lopez V. et al., 2023/01/03. Cancers, 15 (1) p. 316. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2263B25B85EB]
 
An interprofessional medication adherence program to optimize adherence to oral anticancer therapies: a randomized-controlled trial
Bandiera C., Cardoso E., Locatelli I., Digklia A., Zaman K., Diciolla A., Cristina V., Stravodimou A., Lopez V.A., Dolcan A. et al., 2023., 26th International Society for Medication Adherence (ESPACOMP) Conference p. 269 dans International Journal of Clinical Pharmacy. Peer-reviewed.
[DOI][Pmid][serval:BIB_944A7B3041CF]
 
Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial.
Peters S., Letovanec I., Mauer M., Dafni U., Ejedepang D., Biernat W., Bubendorf L., Warth A., Pokharel S., Reinmuth N. et al., 2023/01. Lung cancer, 175 pp. 141-151. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_39ABDF31542A]
 
Expanding Therapeutic Frontiers: CEACAM5 as a Therapeutic Target in Lung Cancer
Peters Solange, 2023/01. Oncology-New York, 37 (1) pp. 40-42.
[WoS][serval:BIB_ED01F2B48586]
High-dose alectinib for RET fusion-positive non-small cell lung cancer in the Blood First Assay Screening Trial.
Dziadziuszko R., Peled N., Mok T., Peters S., Aix S.P., Alatorre-Alexander J., Vicuna B.D., Maclennan M., Bhagawati-Prasad V., Shagan S.M. et al., 2023. Contemporary oncology, 27 (4) pp. 217-223. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2106BCEFA0A7]
 
Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19
Bakouny Ziad, Labaki Chris, Grover Punita, Awosika Joy, Gulati Shuchi, Hsu Chih-Yuan, Alimohamed Saif I., Bashir Babar, Berg Stephanie, Bilen Mehmet A. et al., 2023/01/01. JAMA Oncology, 9 (1) p. 128.
[DOI][WoS][Pmid][serval:BIB_41138DAA93B2]
 
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817.
Paz-Ares L.G., Ciuleanu T.E., Pluzanski A., Lee J.S., Gainor J.F., Otterson G.A., Audigier-Valette C., Ready N., Schenker M., Linardou H. et al., 2023/01. Journal of thoracic oncology, 18 (1) pp. 79-92. Peer-reviewed.
[DOI][Pmid][serval:BIB_0FB9CAD0B375]
2022
A differential process mining analysis of COVID-19 management for cancer patients.
Cuendet M.A., Gatta R., Wicky A., Gerard C.L., Dalla-Vale M., Tavazzi E., Michielin G., Delyon J., Ferahta N., Cesbron J. et al., 2022/12/07. Frontiers in oncology, 12 p. 1043675. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_98AD494947E5]
Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell lung cancer receiving alectinib.
Dziadziuszko R., Peters S., Ruf T., Cardona A., Guerini E., Kurtsikidze N., Smoljanovic V., Planchard D., 2022/12. ESMO open, 7 (6) p. 100612. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6AC5881EE42A]
Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project.
Rüschoff J.H., Haberecker M., Tsourti Z., Nackaerts K., de Perrot M., Brcic L., Nadal E., Tsimpoukis S., Gray S.G., Ampollini L. et al., 2022/12. Modern pathology, 35 (12) pp. 1888-1899. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_21A2AA0732D5]
 
Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment.
Furrer K., Weder W., Eboulet E.I., Betticher D., Pless M., Stupp R., Krueger T., Perentes J.Y., Schmid R.A., Lardinois D. et al., 2022/12. The Journal of thoracic and cardiovascular surgery, 164 (6) pp. 1587-1602.e5. Peer-reviewed.
[DOI][Pmid][serval:BIB_85FE22283C7C]
 
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Haanen J., Obeid M., Spain L., Carbonnel F., Wang Y., Robert C., Lyon A.R., Wick W., Kostine M., Peters S. et al., 2022/12. Annals of oncology, 33 (12) pp. 1217-1238. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F3804F73BCD6]
 
Prognostic impact of tumour mutational burden in resected stage I and II lung adenocarcinomas from a European Thoracic Oncology Platform Lungscape cohort.
Bubendorf L., Zoche M., Dafni U., Rüschoff J.H., Prince S.S., Marti N., Stavrou A., Kammler R., Finn S.P., Moch H. et al., 2022/12. Lung cancer, 174 pp. 27-35. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4F9A876B9A34]
 
ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe
Vaz-Luis I., Masiero M., Cavaletti G., Cervantes A., Chlebowski R.T., Curigliano G., Felip E., Ferreira A.R., Ganz P.A., Hegarty J. et al., 2022/11. Annals of Oncology, 33 (11) pp. 1119-1133.
[DOI][Pmid][serval:BIB_6B7220949D26]
Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries.
Cortellini A., Dettorre G.M., Dafni U., Aguilar-Company J., Castelo-Branco L., Lambertini M., Gennatas S., Angelis V., Sita-Lumsden A., Rogado J. et al., 2022/11. Journal for immunotherapy of cancer, 10 (11) pp. e005732. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_43EB088625EB]
Patients' experiences with cancer care in Switzerland: Results of a multicentre cross-sectional survey.
Arditi C., Eicher M., Colomer-Lahiguera S., Bienvenu C., Anchisi S., Betticher D., Dietrich P.Y., Duchosal M., Peters S., Peytremann-Bridevaux I., 2022/11. European journal of cancer care, 31 (6) pp. e13705. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0C98FBD02368]
 
Correction to: Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project
Rüschoff Jan Hendrik, Haberecker Martina, Tsourti Zoi, Nackaerts Kristiaan, de Perrot Marc, Brcic Luka, Nadal Ernest, Tsimpoukis Sotirios, Gray Steven G., Ampollini Luca et al., 2022/10/17..
[DOI][WoS][Pmid][serval:BIB_098139D32FFB]
 
Minus Times Minus Equals Plus.
Haanen J., Peters S., 2022/10/10. Journal of clinical oncology, 40 (29) pp. 3453-3455. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5A1E1EED8DF6]
 
Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial.
Felip E., Smit E.F., Molina-Vila M.A., Dafni U., Massuti B., Berghmans T., de Marinis F., Passiglia F., Dingemans A.C., Cobo M. et al., 2022/10. Lung cancer, 172 pp. 94-99. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A1D5ACC49E2E]
Diagnostic work-up and systemic treatment for advanced non-squamous non-small-cell lung cancer in four Southeast Asian countries.
Soo R., Mery L., Bardot A., Kanesvaran R., Keong T.C., Pongnikorn D., Prasongsook N., Hutajulu S.H., Irawan C., Manan A.A. et al., 2022/10. ESMO open, 7 (5) p. 100560. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2C2E664EBE7E]
First communication on the efficacy of combined 177Lutetium-PSMA with immunotherapy outside prostate cancer.
Digklia A., Boughdad S., Homicsko K., Dromain C., Trimech M., Dolcan A., Peters S., Prior J., Schaefer N., 2022/10. Journal for immunotherapy of cancer, 10 (10) pp. e005383. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_923D116CD173]
 
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.
O'Brien M., Paz-Ares L., Marreaud S., Dafni U., Oselin K., Havel L., Esteban E., Isla D., Martinez-Marti A., Faehling M. et al., 2022/10. The Lancet. Oncology, 23 (10) pp. 1274-1286. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AB45342CF3A7]
Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events.
Coukos A., Vionnet J., Obeid M., Bouchaab H., Peters S., Latifyan S., Wicky A., Michielin O., Chtioui H., Moradpour D. et al., 2022/10. Journal for immunotherapy of cancer, 10 (10) pp. e005635. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F836C2B098EA]
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy).
Ascierto P.A., Agarwala S.S., Blank C., Caracò C., Carvajal R.D., Ernstoff M.S., Ferrone S., Fox B.A., Gajewski T.F., Garbe C. et al., 2022/09/04. Journal of translational medicine, 20 (1) p. 391. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4E798A46CDF9]
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.
Peters S., Dziadziuszko R., Morabito A., Felip E., Gadgeel S.M., Cheema P., Cobo M., Andric Z., Barrios C.H., Yamaguchi M. et al., 2022/09. Nature medicine, 28 (9) pp. 1831-1839. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D64BF6CDC58E]
 
Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches.
Cortiula F., Reymen B., Peters S., Van Mol P., Wauters E., Vansteenkiste J., De Ruysscher D., Hendriks LEL, 2022/09. Annals of oncology, 33 (9) pp. 893-908. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2C9FA7FE4F90]
An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves.
Wysocki O., Zhou C., Rogado J., Huddar P., Shotton R., Tivey A., Albiges L., Angelakas A., Arnold D., Aung T. et al., 2022/08/16. Cancers, 14 (16) p. 3931. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AB438C1281CE]
Real-world survival outcomes in patients with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other than targeted TRK inhibitors
Hibar Derrek P., Demetri George D., Peters Solange, Davies Jessica, Humblet Olivier, Maund Sophia L., Perez Laura, 2022/08/08. PLOS ONE, 17 (8) pp. e0270571.
[URN][DOI][Pmid][serval:BIB_A5401C2FA2EC]
Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis.
Bestvina C.M., Whisenant J.G., Torri V., Cortellini A., Wakelee H., Peters S., Roca E., De Toma A., Hirsch F.R., Mamdani H. et al., 2022/08. JTO clinical and research reports, 3 (8) p. 100335. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_EBBB31952F9C]
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer.
Kanesvaran R., Castro E., Wong A., Fizazi K., Chua MLK, Zhu Y., Malhotra H., Miura Y., Lee J.L., Chong FLT et al., 2022/08. ESMO open, 7 (4) p. 100518. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EA8968ED0707]
 
Setting the Benchmark for KRAS G12C -Mutated NSCLC.
Passaro A., Peters S., 2022/07/14. The New England journal of medicine, 387 (2) pp. 180-183. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0707DF81346A]
 
A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial.
Luigi Banna G., Addeo A., Zygoura P., Tsourti Z., Popat S., Curioni-Fontecedro A., Nadal E., Shah R., Pope A., Fisher P. et al., 2022/07. Lung cancer, 169 pp. 77-83. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8EE8C213DF72]
Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects.
Peters S., Paz-Ares L., Herbst R.S., Reck M., 2022/07. Journal for immunotherapy of cancer, 10 (7) pp. e004863. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_94A63A329C06]
Cancers professionnels : l’essentiel pour le médecin au cabinet [Occupational cancers: essentials for the general practioners]
Krief P., Cohidon C., Turcu V., Rinaldo M., Kamara M., Koller M., Zyska Cherix A., Senn N., Peters S., 2022/06/29. Revue medicale suisse, 18 (788) pp. 1313-1321. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_A5BC2572EB3B]
 
Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455].
König D., Schär S., Vuong D., Guckenberger M., Furrer K., Opitz I., Weder W., Rothschild S.I., Ochsenbein A., Zippelius A. et al., 2022/06. ESMO open, 7 (3) p. 100494. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_74C3D3CD6DB5]
COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE).
Castelo-Branco L., Tsourti Z., Gennatas S., Rogado J., Sekacheva M., Viñal D., Lee R., Croitoru A., Vitorino M., Khallaf S. et al., 2022/06. ESMO open, 7 (3) p. 100499. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_880DB2367FE3]
Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis.
Dafni U., Soo R.A., Peters S., Tsourti Z., Zygoura P., Vervita K., Han J.Y., De Castro J., Coate L., Früh M. et al., 2022/06. ESMO open, 7 (3) p. 100507. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EABD7EDC5C76]
Thérapies ciblées et carcinomes non à petites cellules : nouveautés [Targeted therapies and non-small cell carcinomas : novelties]
Stauber R., Gro S L., Nguyen-Ngoc T., Mederos N., Bouchaab H., Peters S., Abdelhamid K., 2022/05/18. Revue medicale suisse, 18 (782) pp. 970-975. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_FB698780FC89]
Une période de terreur et de défis : quand verrons-nous ce monde meilleur ?
Dietrich P.Y., Aapro M., Peters S., 2022/05/18. Revue medicale suisse, 18 (782) pp. 967-968. Peer-reviewed.
[URN][DOI][serval:BIB_146AF71DA32B]
Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial.
Dziadziuszko R., Peters S., Mok T., Camidge D.R., Gadgeel S.M., Ou S.I., Konopa K., Noé J., Nowicka M., Bordogna W. et al., 2022/05/02. Clinical cancer research, 28 (9) pp. 1800-1808. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_67ED3D3777DA]
A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry.
Whisenant J.G., Baena J., Cortellini A., Huang L.C., Lo Russo G., Porcu L., Wong S.K., Bestvina C.M., Hellmann M.D., Roca E. et al., 2022/05. Journal of thoracic oncology, 17 (5) pp. 661-674. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8A000CE08497]
CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer.
De Ruysscher D., Ramalingam S., Urbanic J., Gerber D.E., Tan DSW, Cai J., Li A., Peters S., 2022/05. Clinical lung cancer, 23 (3) pp. e264-e268. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_800C38154E47]
 
Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data.
Pérol M., Felip E., Dafni U., Polito L., Pal N., Tsourti Z., Ton TGN, Merritt D., Morris S., Stahel R. et al., 2022/05. Annals of oncology, 33 (5) pp. 511-521. Peer-reviewed.
[DOI][Pmid][serval:BIB_179CC1EDD39A]
 
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer.
Passaro A., Leighl N., Blackhall F., Popat S., Kerr K., Ahn M.J., Arcila M.E., Arrieta O., Planchard D., de Marinis F. et al., 2022/05. Annals of oncology, 33 (5) pp. 466-487. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3A6B7045371A]
Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital.
Lee R.J., Wysocki O., Zhou C., Shotton R., Tivey A., Lever L., Woodcock J., Albiges L., Angelakas A., Arnold D. et al., 2022/05. JCO clinical cancer informatics, 6 pp. e2100177. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A5BE25E8275C]
First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.
Scherpereel A., Antonia S., Bautista Y., Grossi F., Kowalski D., Zalcman G., Nowak A.K., Fujimoto N., Peters S., Tsao A.S. et al., 2022/05. Lung cancer, 167 pp. 8-16. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A48722CEDE6A]
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.
Peters S., Scherpereel A., Cornelissen R., Oulkhouir Y., Greillier L., Kaplan M.A., Talbot T., Monnet I., Hiret S., Baas P. et al., 2022/05. Annals of oncology, 33 (5) pp. 488-499. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_78CBA16F62E5]
Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients.
Obeid M., Suffiotti M., Pellaton C., Bouchaab H., Cairoli A., Salvadé V., Stevenel C., Hottinger R., Pythoud C., Coutechier L. et al., 2022/05/01. JAMA oncology, 8 (5) pp. e220446. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8956034C5615]
Histological and molecular plasticity of ALK-positive non-small-cell lung cancer under targeted therapy: a case report.
Ball M., Christopoulos P., Kirchner M., Allgäuer M., Brandt R., Winter H., Heußel C.P., Herth F., Fröhling S., Savai R. et al., 2022/04. Cold Spring Harbor molecular case studies, 8 (3) pp. a006156. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_1A3C674BFA41]
Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials.
König D., Schär S., Vuong D., Guckenberger M., Furrer K., Opitz I., Weder W., Rothschild S.I., Ochsenbein A., Zippelius A. et al., 2022/04. ESMO open, 7 (2) p. 100455. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3670D738F077]
Verzögerte Diagnose eines Lungenkarzinoms, das sich als choroidale Metastase in einem COVID-19-Patienten präsentierte und am Anfang mit Osimertinib behandelt wurde [Delayed Diagnosis of Lung Carcinoma Presenting as Choroidal Metastasis in a COVID-19 Patient and Initially Treated with Osimertinib]
Haeller C.N., Khamsy L., Kloepper J., Schiappacasse L., Bouchaab H., Peters S., Schalenbourg A., 2022/04. Klinische Monatsblatter fur Augenheilkunde, 239 (4) pp. 586-589. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B66EE0FBC45A]
 
VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study
Paz-Ares L., O'Brien M.E.R., Mauer M., Dafni U., Oselin K., Havel L., Esteban Gonzalez E., Isla D., Martinez-Marti A., Faehling M. et al., 2022/04. Annals of Oncology, 33 (4) pp. 451-453.
[DOI][WoS][serval:BIB_5EB0E80DC3F2]
 
Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer
Fu Julie, Reid Sonya A., French Benjamin, Hennessy Cassandra, Hwang Clara, Gatson Na Tosha, Duma Narjust, Mishra Sanjay, Nguyen Ryan, Hawley Jessica E. et al., 2022/03/28. JAMA Network Open, 5 (3) pp. e224304.
[DOI][WoS][Pmid][serval:BIB_4468EB901809]
COVID-19 vaccination and breakthrough infections in patients with cancer
Schmidt A.L., Labaki C., Hsu C.-Y., Bakouny Z., Balanchivadze N., Berg S.A., Blau S., Daher A., El Zarif T., Friese C.R. et al., 2022/03. Annals of Oncology, 33 (3) pp. 340-346.
[URN][DOI][WoS][Pmid][serval:BIB_C847E8167D45]
 
Efficacy of targeted therapies for oncogene-driven lung cancer in early single-arm versus late phase randomized clinical trials: A comparative analysis.
Tan A.C., Tan S.H., Zhou S., Peters S., Curigliano G., Tan DSW, 2022/03. Cancer treatment reviews, 104 p. 102354. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BFD000998B6C]
 
Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies.
Passaro A., Brahmer J., Antonia S., Mok T., Peters S., 2022/02/20. Journal of clinical oncology, 40 (6) pp. 598-610. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4FF2DE2E645B]
Oncologie [2021 Oncology update]
Meyer M.L., Chrysou K., Stamatiou A., Gilabert M., Herrera Gomez R.G., Latifyan S., Masmoudi S., Mederos N., Perrinjaquet C., Berthold D. et al., 2022/02/02. Revue medicale suisse, 18 (767) pp. 182-186. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_BB8819FD3196]
 
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
Soo R.A., Han J.Y., Dafni U., Cho B.C., Yeo C.M., Nadal E., Carcereny E., de Castro J., Sala M.A., Bernabé R. et al., 2022/02. Annals of oncology, 33 (2) pp. 181-192. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6A6669A4204F]
 
Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma.
Budczies J., Kirchner M., Kluck K., Kazdal D., Glade J., Allgäuer M., Kriegsmann M., Heußel C.P., Herth F.J., Winter H. et al., 2022/02. Cancer immunology, immunotherapy, 71 (2) pp. 251-265. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0DB753CF82DB]
Erratum: Perception and Improvisation of Gender Climate in Oncology and Role of International and National Societies
Bajpai Jyoti, Mailankody Sharada, Garrido Pilar, Peters Solange, 2022/02. Indian Journal of Medical and Paediatric Oncology, 43 (01) pp. e1-e1.
[URN][DOI][WoS][serval:BIB_C3B409B4C90A]
First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology.
Gridelli C., Peters S., Mok T., Forde P.M., Reck M., Attili I., de Marinis F., 2022/02. ESMO open, 7 (1) p. 100355. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3AF0144EC613]
Perception and Improvisation of Gender Climate in Oncology and Role of International and National Societies
Bajpai Jyoti, Mailankody Sharada, Garrido Pilar, Peters Solange, 2022/02. Indian Journal of Medical and Paediatric Oncology, 43 (01) pp. 004-007.
[URN][DOI][WoS][serval:BIB_E5E72205B561]
The impact of COVID-19 on cancer care and oncology clinical research: an experts' perspective.
Sessa C., Cortes J., Conte P., Cardoso F., Choueiri T., Dummer R., Lorusso P., Ottmann O., Ryll B., Mok T. et al., 2022/02. ESMO open, 7 (1) p. 100339. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3E779B64CA41]
WHO-ESMO collaboration in cancer control: policies into action to save lives.
Mikkelsen B., Peters S., 2022/02. ESMO open, 7 (1) p. 100373. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_72D6021F3228]
 
Targeting HER2-Mutant NSCLC - The Light Is On.
Passaro A., Peters S., 2022/01/20. The New England journal of medicine, 386 (3) pp. 286-289. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_934F0D17F639]
 
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial.
Peters S., Pujol J.L., Dafni U., Dómine M., Popat S., Reck M., Andrade J., Becker A., Moro-Sibilot D., Curioni-Fontecedro A. et al., 2022/01. Annals of oncology, 33 (1) pp. 67-79. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_82275164BC57]
Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies.
Michielin O., Lalani A.K., Robert C., Sharma P., Peters S., 2022/01. Journal for immunotherapy of cancer, 10 (1) pp. e003024. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8EB4E8449258]
Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2).
Peters S., Galle P.R., Bernaards C.A., Ballinger M., Bruno R., Quarmby V., Ruppel J., Vilimovskij A., Wu B., Sternheim N. et al., 2022/01. Clinical and translational science, 15 (1) pp. 141-157. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_527DB42F25A1]
Gallbladder cancer during pregnancy treated with surgery and adjuvant gemcitabine: A case report and review of the literature.
Diciolla A., Gianoni M., Fleury M., Szturz P., Demartines N., Peters S., Duran R., Desseauve D., Panchaud M.A., Fasquelle F. et al., 2022. Frontiers in oncology, 12 p. 1006387. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_83C6E9C8B673]
2021
 
Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort.
Dziadziuszko R., Mok T., Peters S., Han J.Y., Alatorre-Alexander J., Leighl N., Sriuranpong V., Pérol M., de Castro Junior G., Nadal E. et al., 2021/12. Journal of thoracic oncology, 16 (12) pp. 2040-2050. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6A6B08E8EC98]
 
Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer.
Schoenfeld A.J., Antonia S.J., Awad M.M., Felip E., Gainor J., Gettinger S.N., Hodi F.S., Johnson M.L., Leighl N.B., Lovly C.M. et al., 2021/12. Annals of oncology, 32 (12) pp. 1597-1607. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D6DEE26F8042]
 
COVID-19 and Cancer: A Review of the Registry-Based Pandemic Response.
Desai A., Mohammed T.J., Duma N., Garassino M.C., Hicks L.K., Kuderer N.M., Lyman G.H., Mishra S., Pinato D.J., Rini B.I. et al., 2021/12/01. JAMA oncology, 7 (12) pp. 1882-1890. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5B7F58C6E972]
 
Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy.
Remon J., Soria J.C., Peters S., ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org, 2021/12. Annals of oncology, 32 (12) pp. 1637-1642. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_38CABBD2FC4C]
Female leadership in oncology-has progress stalled? Data from the ESMO W4O authorship and monitoring studies.
Berghoff A.S., Sessa C., Yang J.C., Tsourti Z., Tsang J., Tabernero J., Peters S., Linardou H., Letsch A., Haanen J. et al., 2021/12. ESMO open, 6 (6) p. 100281. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_427B300443B4]
Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck.
Keam B., Machiels J.P., Kim H.R., Licitra L., Golusinski W., Gregoire V., Lee Y.G., Belka C., Guo Y., Rajappa S.J. et al., 2021/12. ESMO open, 6 (6) p. 100309. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_225488014D1A]
 
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer.
Yoshino T., Argilés G., Oki E., Martinelli E., Taniguchi H., Arnold D., Mishima S., Li Y., Smruti B.K., Ahn J.B. et al., 2021/12. Annals of oncology, 32 (12) pp. 1496-1510. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0E76CBC7CD04]
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma.
Kanesvaran R., Porta C., Wong A., Powles T., Ng Q.S., Schmidinger M., Ye D., Malhotra H., Miura Y., Lee J.L. et al., 2021/12. ESMO open, 6 (6) p. 100304. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_83EBCC2DD97D]
 
Early discharge after thoracoscopic anatomical pulmonary resection for non-small-cell lung cancer.
Forster C., Perentes J.Y., Ojanguren A., Abdelnour-Berchtold E., Zellweger M., Bouchaab H., Peters S., Krueger T., Gonzalez M., 2021/11/22. Interactive cardiovascular and thoracic surgery, 33 (6) pp. 892-898. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E6AB61794067]
 
Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials.
Peters S., Danson S., Ejedepang D., Dafni U., Hasan B., Radcliffe H.S., Bustin F., Crequit J., Coate L., Guillot M. et al., 2021/11. Lung cancer, 161 pp. 76-85. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_213E1391F9A7]
 
EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours.
Le Rhun E., Guckenberger M., Smits M., Dummer R., Bachelot T., Sahm F., Galldiks N., de Azambuja E., Berghoff A.S., Metellus P. et al., 2021/11. Annals of oncology, 32 (11) pp. 1332-1347. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_689733AC5486]
Quantification of the spatial distribution of primary tumors in the lung to develop new prognostic biomarkers for locally advanced NSCLC.
Vuong D., Bogowicz M., Wee L., Riesterer O., Vlaskou Badra E., D'Cruz L.A., Balermpas P., van Timmeren J.E., Burgermeister S., Dekker A. et al., 2021/10/22. Scientific reports, 11 (1) p. 20890. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B2FF32E1158E]
68Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis.
Boughdad S., Latifyan S., Fenwick C., Bouchaab H., Suffiotti M., Moslehi J.J., Salem J.E., Schaefer N., Nicod-Lalonde M., Costes J. et al., 2021/10. Journal for immunotherapy of cancer, 9 (10) pp. e003594. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6D88B7F593BA]
Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology.
Castelo-Branco L., Awada A., Pentheroudakis G., Perez-Gracia J.L., Mateo J., Curigliano G., Banerjee S., Giuliani R., Lordick F., Cervantes A. et al., 2021/10. ESMO open, 6 (5) p. 100237. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4A3F20502CAC]
Impact of COVID-19 on cancer service delivery: a follow-up international survey of oncology clinicians.
Chazan G., Franchini F., Alexander M., Banerjee S., Mileshkin L., Blinman P., Zielinski R., Karikios D., Pavlakis N., Peters S. et al., 2021/10. ESMO open, 6 (5) p. 100224. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C2A577E9F0A6]
The CoVID-TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19.
Li A., Kuderer N.M., Hsu C.Y., Shyr Y., Warner J.L., Shah D.P., Kumar V., Shah S., Kulkarni A.A., Fu J. et al., 2021/10. Journal of thrombosis and haemostasis, 19 (10) pp. 2522-2532. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2EAD54EA1A35]
 
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.
Rothschild S.I., Zippelius A., Eboulet E.I., Savic Prince S., Betticher D., Bettini A., Früh M., Joerger M., Lardinois D., Gelpke H. et al., 2021/09/10. Journal of clinical oncology, 39 (26) pp. 2872-2880. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9646C9E25D4B]
 
Imaging Features of Pulmonary Immune-related Adverse Events.
Pozzessere C., Lazor R., Jumeau R., Peters S., Prior J.O., Beigelman-Aubry C., 2021/09. Journal of thoracic oncology, 16 (9) pp. 1449-1460. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_42CE5369FFE3]
Preselection of robust radiomic features does not improve outcome modelling in non-small cell lung cancer based on clinical routine FDG-PET imaging.
Oliveira C., Amstutz F., Vuong D., Bogowicz M., Hüllner M., Foerster R., Basler L., Schröder C., Eboulet E.I., Pless M. et al., 2021/08/21. EJNMMI research, 11 (1) p. 79. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A190AD7F0236]
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation.
Maio M., Lahn M., Di Giacomo A.M., Covre A., Calabrò L., Ibrahim R., Fox B., Siena Think Tank, 2021/07/23. Journal of experimental & clinical cancer research, 40 (1) p. 240. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E27207EDCAD2]
 
ESMO pays tribute to Professor José Baselga.
Peters S., Tabernero J., Cervantes A., Banerjee S., Giuliani R., Lordick F., 2021/07. Annals of oncology, 32 (7) pp. 823-824. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AB7BDD49CD7C]
Neutrophils in the era of immune checkpoint blockade.
Faget J., Peters S., Quantin X., Meylan E., Bonnefoy N., 2021/07. Journal for immunotherapy of cancer, 9 (7) pp. e002242. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4BDDB5E5C55B]
 
Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC).
Garon E.B., Cho B.C., Reinmuth N., Lee K.H., Luft A., Ahn M.J., Robinet G., Le Moulec S., Natale R., Schneider J. et al., 2021/07. Clinical lung cancer, 22 (4) pp. 301-312.e8. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_29D565681F08]
 
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>☆</sup>.
Dingemans A.C., Früh M., Ardizzoni A., Besse B., Faivre-Finn C., Hendriks L.E., Lantuejoul S., Peters S., Reguart N., Rudin C.M. et al., 2021/07. Annals of oncology, 32 (7) pp. 839-853. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E3B6947CE94F]
 
VP3-2021: A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial
Soo R., Han J-Y., Dimopoulou G., Cho B.C., Yeo C.M., Nadal E., Carcereny E., de Castro J., Sala M.A., Bernabe R. et al., 2021/07. Annals of Oncology, 32 (7) pp. 942-944.
[DOI][WoS][serval:BIB_E123EA0B584E]
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium.
Grivas P., Khaki A.R., Wise-Draper T.M., French B., Hennessy C., Hsu C.Y., Shyr Y., Li X., Choueiri T.K., Painter C.A. et al., 2021/06. Annals of oncology, 32 (6) pp. 787-800. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_A7A24C418B5A]
ESMO pays tribute to Professor José Baselga.
Peters S., Tabernero J., Cervantes A., Banerjee S., Giuliani R., Lordick F., 2021/06. ESMO open, 6 (3) p. 100130. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D5A244B4A45D]
Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey.
Garrido P., Adjei A.A., Bajpai J., Banerjee S., Berghoff A.S., Choo S.P., Felip E., Furness AJS, Garralda E., Haanen J. et al., 2021/06. ESMO open, 6 (3) p. 100131. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CAF2BC9777BE]
Nongenetic Evolution Drives Lung Adenocarcinoma Spatial Heterogeneity and Progression.
Tavernari D., Battistello E., Dheilly E., Petruzzella A.S., Mina M., Sordet-Dessimoz J., Peters S., Krueger T., Gfeller D., Riggi N. et al., 2021/06. Cancer discovery, 11 (6) pp. 1490-1507. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F6D4BAEDCE1E]
 
Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project.
Finn S.P., Addeo A., Dafni U., Thunnissen E., Bubendorf L., Madsen L.B., Biernat W., Verbeken E., Hernandez-Losa J., Marchetti A. et al., 2021/06. Journal of thoracic oncology, 16 (6) pp. 990-1002. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_13B0DD5F94DD]
 
Treatment Decisions for Patients with Cancer during the COVID-19 Pandemic.
Labaki C., Peters S., Choueiri T.K., 2021/06. Cancer discovery, 11 (6) pp. 1330-1335. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A12F230673D5]
Oncologie et pandémie de Covid-19 : les patients au cœur des enjeux.
Dietrich P.Y., Aapro M., Peters S., 2021/05/19. Revue medicale suisse, 17 (739) p. 955. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_ECB4219DB1D9]
 
GLUT1 Expression in Tumor-Associated Neutrophils Promotes Lung Cancer Growth and Resistance to Radiotherapy.
Ancey P.B., Contat C., Boivin G., Sabatino S., Pascual J., Zangger N., Perentes J.Y., Peters S., Abel E.D., Kirsch D.G. et al., 2021/05/01. Cancer research, 81 (9) pp. 2345-2357. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A171D8D09919]
 
Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs.
Felip E., Shaw A.T., Bearz A., Camidge D.R., Solomon B.J., Bauman J.R., Bauer T.M., Peters S., Toffalorio F., Abbattista A. et al., 2021/05. Annals of oncology, 32 (5) pp. 620-630. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_37A8F854B2F7]
 
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy.
Ghisoni E., Wicky A., Bouchaab H., Imbimbo M., Delyon J., Gautron Moura B., Gérard C.L., Latifyan S., Özdemir B.C., Caikovski M. et al., 2021/05. European journal of cancer, 149 pp. 153-164. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4791AD7F437D]
 
Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations.
Passaro A., Mok T., Peters S., Popat S., Ahn M.J., de Marinis F., 2021/05. Journal of thoracic oncology, 16 (5) pp. 764-773. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C53093BF243E]
 
Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331<sup>☆</sup>.
Spigel D.R., Vicente D., Ciuleanu T.E., Gettinger S., Peters S., Horn L., Audigier-Valette C., Pardo Aranda N., Juan-Vidal O., Cheng Y. et al., 2021/05. Annals of oncology, 32 (5) pp. 631-641. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4545F4DBDC90]
The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: Vaccinate. Monitor. Educate.
Garassino M.C., Vyas M., de Vries EGE, Kanesvaran R., Giuliani R., Peters S., European Society for Medical Oncology, 2021/05. Annals of oncology, 32 (5) pp. 579-581. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AF4BDC63F4F5]
 
VP2-2021: Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small cell lung cancer (Nsq-NSCLC) with high PD-L1 expression using real-world data
Peters S., Dafni U., Perol M., Felip E., Polito L., Pal N., Ton T.G.N., Merritt D., Morris S., Stahel R.A., 2021/05. Annals of Oncology, 32 (5) pp. 687-688.
[DOI][WoS][serval:BIB_3634E1D8C4C5]
Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451.
Owonikoko T.K., Park K., Govindan R., Ready N., Reck M., Peters S., Dakhil S.R., Navarro A., Rodríguez-Cid J., Schenker M. et al., 2021/04/20. Journal of clinical oncology, 39 (12) pp. 1349-1359. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_78F0D04B7BA3]
Suivi téléphonique des patients testés positifs au SARS-CoV-2 au Département d’oncologie du CHUV [Telephone follow-up of SARS-CoV-2 positive patients at the Oncology Department of Lausanne University Hospital]
Jankovic J., Da Silva Lopes A.M., Morez A., Darnac C., Demicheli R., Dalla-Vale M., Lauriers N., Garcia Sanchez J., Bouchaab H., Ninane F. et al., 2021/04/07. Revue medicale suisse, 17 (733) pp. 703-707. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_B502B1BCD7F4]
Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma.
Kazdal D., Rempel E., Oliveira C., Allgäuer M., Harms A., Singer K., Kohlwes E., Ormanns S., Fink L., Kriegsmann J. et al., 2021/04. Translational lung cancer research, 10 (4) pp. 1666-1678. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BA9CF3C21C49]
Impact of COVID-19 on social media as perceived by the oncology community: results from a survey in collaboration with the European Society for Medical Oncology (ESMO) and the OncoAlert Network.
Morgan G., Tagliamento M., Lambertini M., Devnani B., Westphalen B., Dienstmann R., Bozovic-Spasojevic I., Calles A., Criscitiello C., Curioni A. et al., 2021/04. ESMO open, 6 (2) p. 100104. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_342B627B94E0]
OncoAlert Round Table Discussions: The Global COVID-19 Experience.
Morgan G., de Azambuja E., Punie K., Ades F., Heinrich K., Personeni N., Rahme R., Ferrara R., Pels K., Garassino M. et al., 2021/04. JCO global oncology, 7 pp. 455-463. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_0A9B77FD6F7E]
 
Overcoming therapy resistance in EGFR-mutant lung cancer
Passaro Antonio, Jänne Pasi A., Mok Tony, Peters Solange, 2021/04. Nature Cancer, 2 (4) pp. 377-391.
[DOI][WoS][serval:BIB_67E3EEBBA705]
 
The Promising Evolution of Targeted Therapeutic Strategies in Cancer.
Peters S., Mok T., Passaro A., Jänne P.A., 2021/04. Cancer discovery, 11 (4) pp. 810-814. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C4A6BE00E890]
 
A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study.
Si H., Kuziora M., Quinn K.J., Helman E., Ye J., Liu F., Scheuring U., Peters S., Rizvi N.A., Brohawn P.Z. et al., 2021/03/15. Clinical cancer research, 27 (6) pp. 1631-1640. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1004EC355F9F]
Abscopal effect in a patient with malignant pleural mesothelioma treated with palliative radiotherapy and pembrolizumab.
Mampuya W.A., Bouchaab H., Schaefer N., Kinj R., La Rosa S., Letovanec I., Ozsahin M., Bourhis J., Coukos G., Peters S. et al., 2021/03. Clinical and translational radiation oncology, 27 pp. 85-88. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C82F89BA6EDB]
ESMO pays tribute to Professor José Baselga.
Peters S., Tabernero J., Cervantes A., Banerjee S., Giuliani R., Lordick F., 2021/03. Immuno-oncology technology, 9 p. 100027. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_088E6B728DE3]
Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel.
Gandara D., Reck M., Moro-Sibilot D., Mazieres J., Gadgeel S., Morris S., Cardona A., Mendus D., Ballinger M., Rittmeyer A. et al., 2021/03. Journal for immunotherapy of cancer, 9 (3) pp. e001882. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_475BFAD3DFC0]
Severity of COVID-19 in patients with lung cancer: evidence and challenges.
Passaro A., Bestvina C., Velez Velez M., Garassino M.C., Garon E., Peters S., 2021/03. Journal for immunotherapy of cancer, 9 (3) pp. e002266. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_65ACCD8023E1]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University